Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide (CoCa)

AstraZeneca

Status: Completed

Conditions: Essential Hypertension

Study type: Observational

Funder types: Industry

Identifiers

NCT00608153

NIS-CGE-ATA-2007/1

Details and patient eligibility

About

The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.

Enrollment: 1,773 patients

Sex

Volunteers: No Healthy Volunteers

Inclusion criteria

• essential hypertension
• under candesartan treatment

Exclusion criteria

Trial design

1,773 participants in 1 patient group

1

Description:

Patient with essential hypertension under treatment with candesartan or candesartan HCT